According to research published in the Journal of Infectious Diseases, scientists at Trinity College Dublin and St. James’s Hospital have found that the anti-inflammatory steroid dexamethasone can reduce harmful lung inflammation triggered by Mycobacterium avium without weakening the immune system’s core ability to control the infection. This discovery suggests that dexamethasone could serve as a valuable adjuvant treatment for nontuberculous mycobacterial (NTM) disease, offering relief to patients who suffer from persistent inflammation even while undergoing lengthy antibiotic courses.
Understanding NTM Disease and the Challenge of Chronic Inflammation
Nontuberculous mycobacterial infections present a growing global health challenge, particularly for individuals living with chronic lung disease. According to researchers at the Trinity Translational Medicine Institute, standard treatment for NTM infections typically requires prolonged courses of multiple antibiotics. However, many patients continue to experience debilitating symptoms driven by persistent inflammation rather than active bacterial proliferation alone. Clinicians have traditionally avoided prescribing steroids during NTM infections due to longstanding concerns about suppressing vital T cell immune responses. Dr. Donal Cox, senior author of the research, noted that fine-tuning this immune response by reducing damaging inflammation while preserving core defenses could transform patient care. Current treatment strategies focus primarily on killing the bacteria, but controlling tissue-damaging inflammation offers a gateway to more effective therapies.
How Dexamethasone Affects Human Macrophages
To investigate how immune cells respond to infection under steroid treatment, the Trinity research team focused on human macrophages, which act as the body’s first line of defense against invading pathogens. Using advances in immunometabolism research, the scientists discovered that treating infected macrophages with dexamethasone significantly reduced their infection-driven metabolic activity. This metabolic shift successfully lowered the production of key inflammatory signals without increasing bacterial growth within the cells. Specifically, the study revealed that the production of inflammatory cytokines—including TNF, IL-1β, IL-6, and IL-8—dropped markedly following dexamethasone treatment. These findings demonstrate that inflammatory responses can be successfully separated from bacterial control in human macrophages during a Mycobacterium avium infection.
Potential Impact and Future Directions for Patient Care
The Mycobacterium avium complex represents one of the most common causes of NTM lung disease worldwide. Because chronic inflammation contributes substantially to patient symptoms and a reduced quality of life even during effective antimicrobial treatment, new therapeutic options remain a high priority for clinicians. According to the research team, these findings provide a strong rationale for investigating steroids as potential host-directed therapies to complement existing antimicrobial regimens. Although further clinical studies are required to confirm safety and efficacy in patients, this work establishes a clear biological mechanism showing that dexamethasone can calm destructive lung inflammation without compromising the body’s natural innate immunity.
Related reading